Skip to main content

bulevirtide

bulevirtide: 4 clinical trials tracked.

bulevirtide evidence translation

What we can confirm

4 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about bulevirtide, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 3 study sponsors
Clinical Trial Registry Records (4)

A Phase 2b/3, Open-Label, Multicenter Trial Evaluating the Efficacy and Safety of Switching to Brelovitug for the Treatment of Chronic Hepatitis Delta Infection in Participants Receiving Bulevirtide (AZURE-3)

NCT07454837Registry updated 2026-09-10·Phase 2/Phase 3·MIRM
Recruiting

Primary endpoint: Proportion of participants with undetectable HDV RNA (<LLOQ Target not detected [TND])

InterventionalRandomizedopen120 targetStarted 2026-02Completion 2029-0344 sites · Austria, Czechia, France, Germany…Mirum Pharmaceuticals, Inc.

A Global, Randomized, Open-label, Multicenter Phase 3 Trial Evaluating BJT-778 vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)

NCT07200908Registry updated 2026-10-08·Phase 3·MIRM
Recruiting

Primary endpoint: Percentage of participants with a composite endpoint of virologic response and ALT normalization

InterventionalRandomizedopen172 targetStarted 2025-08Completion 2029-0957 sites · Austria, Czechia, France, Germany…Mirum Pharmaceuticals, Inc.

A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide (ECLIPSE 2)

NCT07128550Registry updated 2026-07-13·Phase 3·VIR
Active, not recruiting

Primary endpoint: HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) at Week 24

InterventionalRandomizedopen150 targetStarted 2025-07Completion 2031-0738 sites · Austria, France, Germany, Italy…Vir Biotechnology, Inc.

A Registry Study of Treatment With Bulevirtide in Participants With Chronic Hepatitis D Infection

NCT05718700Registry updated 2026-09-18·GILD
Terminated

Primary endpoint: Exposure-adjusted Incidence of Participants With Liver-related Event: Hepatic Decompensation, Hepatocellular Carcinoma (HCC), Liver Transplantation, and Liver-related Death

Observational170 enrolledStarted 2023-02Completion 2026-0850 sites · Austria, France, Germany, Romania…Gilead Sciences